


Supplementary Figure S1. Antibody titer after 3 and 6 months from the 2nd dose of BNT162b2 mRNA-based vaccine against SARS-CoV-2 in people with cystic fibrosis naïve to SARS-CoV-2 according to: (a) severity of adverse reactions and occurrence of systemic reactions after the first injection; (b) after the second injection. Grey symbols indicate individual data, black symbols and error bars show the estimated mean values and corresponding 95% confidence intervals obtained from mixed effect regression models. *P*-values indicate the statistical significance of the main effects of severe/moderate adverse reaction or systemic reaction and their interaction with time (3 or 6 months post vaccination).



MSreact: Occurrence of severe/moderate adverse reaction (yes vs no). SYSreact: Occurrence of systemic adverse reaction (yes vs no).